fda semaglutide warning november 2025 The has received reports of adverse events after patients used compounded versions of semaglutide. Some compounders may also be using unapproved salt forms. Patients should avoid compounded when an FDA-approved fda semaglutide compounding warning november

Glucagon-like peptide-1 (GLP-1) receptor agonistsincluding semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), and liraglutide (Victoza, Saxenda)work by mimicking the incretin hormone GLP-1

Key nutritional considerations include: Protein intake: Prioritize lean proteins such as chicken, fish, eggs, legumes, and Greek yogurt at each meal to support hair follicle function

After your initial subcutaneous injection, semaglutide begins binding to receptors throughout your body, triggering changes in appetite, digestion, and metabolism

Blood sugar control suffers as well

Foundational work should include translational trials that pair GLP-1RA therapy with deep immunophenotyping (Th1/Th17/Treg balance, inflammasome activity), adipokine profiling (leptin, adiponectin), and gut-barrier/microbiome readouts, alongside thyroid-specific endpoints (Thyroid Peroxidase Antibodies (TPOAb)/Thyroglobulin Antibodies (TgAb)/TRAb trajectories, ultrasound echogenicity and volume, Doppler vascularity, and patient-reported outcomes) [1,3,9,22]

If you are aged 55 or over with weight loss and upper abdominal pain, reflux or dyspepsia, as these may require urgent referral under NICE suspected cancer guidelines